SLC22A17

SLC22A17 is an atypical member of the SLC22 solute carrier family that functions as both an iron transporter and a receptor for lipocalin-2 (LCN2/NGAL) and other metalloproteins, linking iron homeostasis to cell survival, ferroptosis, and blood-brain barrier integrity across multiple tissues. Its intrinsically disordered N-terminal extracellular domain forms a fuzzy complex with LCN2, preferentially binding the apo (iron-free) form, and mediates receptor-mediated endocytosis of LCN2, transferrin, and metallothionein in the renal distal tubule and collecting duct (PMID:26635366, PMID:37589051). In the brain, SLC22A17 interacts with p62 to modulate Nrf2/HO-1 signaling and iron efflux; conditional knockout causes iron overload, oxidative stress, neural stem cell apoptosis, and cognitive impairment, while in brain endothelial cells it promotes ferroptosis and represses tight junction gene transcription after ischemia (PMID:41397957, PMID:38738428). SLC22A17 expression is transcriptionally regulated by NFAT5, CREB, and Wnt/β-catenin signaling in renal collecting duct cells in response to osmotic and inflammatory stimuli, and it promotes iron-dependent ferroptosis in fibroblasts and endothelial cells (PMID:30404645, PMID:31671521, PMID:41386104).

1. 2011 Medium

   Establishing SLC22A17 as an atypical SLC22 family member resolved the puzzle of why it does not transport canonical organic cation substrates despite its sequence similarity, redirecting the search toward non-canonical transport or receptor functions.

   Evidence Heterologous expression in HEK-293 cells with radioisotope uptake assays showing absence of MPP+ or carnitine transport

   PMID:21359964

   Open questions at the time

   • Actual transported substrate remained unidentified
   • Only canonical SLC22 substrates tested
   • Single cell line used
2. 2015 High

   Structural characterization of the N-terminal domain as intrinsically disordered and preferentially binding apo-LCN2 established the molecular basis for how SLC22A17 discriminates between iron-loaded and iron-free ligand, reframing it as a receptor that fine-tunes LCN2 signaling rather than simply internalizing cargo.

   Evidence Solution-state NMR and biophysical binding affinity measurements; proximity ligation assay confirming interaction in hippocampal neurons with differential effects of apo- versus holo-LCN2 on cell survival

   PMID:26004810 PMID:26635366

   Open questions at the time

   • Full-length receptor structure was unknown
   • Mechanism of LCN2 internalization not resolved
   • Whether apo/holo discrimination occurs in vivo not tested
3. 2018 Medium

   Identification of Wnt/β-catenin, NFAT5, and CREB as transcriptional regulators of SLC22A17 in renal collecting duct cells revealed how osmotic and hormonal cues control its expression, connecting SLC22A17 to kidney physiology and osmotolerance.

   Evidence RNAi silencing of β-catenin and Nfat5, pharmacological CREB inhibition, and TLR4/LPS treatment in primary IMCD and mCCD cells with qPCR and immunoblotting readouts

   PMID:30404645 PMID:31671521

   Open questions at the time

   • Direct promoter binding by these transcription factors not shown (e.g., ChIP)
   • Physiological consequence of transcriptional regulation in vivo not tested
4. 2019 Medium

   Demonstration that SLC22A17 serves as a receptor for the fungal allergen Alt a 1 broadened its ligand repertoire beyond LCN2, suggesting a general role in recognizing lipocalin-fold proteins.

   Evidence Pull-down assay and immunofluorescence in Calu-3 airway epithelial cells with computational structural modeling

   PMID:31095759

   Open questions at the time

   • Functional consequence of Alt a 1 internalization via SLC22A17 on downstream signaling not fully characterized
   • Specificity versus other airway receptors unclear
5. 2023 Medium

   Consolidation of SLC22A17 as a distal nephron receptor mediating endocytosis of multiple metalloproteins (transferrin, metallothionein, LCN2) provided a unified model for how proteins and transition metals escaping the proximal tubule are recaptured, and linked SLC22A17 to cadmium nephrotoxicity and astroglial neurogenesis regulation in Alzheimer's disease.

   Evidence Mechanistic synthesis of multiple renal RME studies; functional knockdown and single-cell transcriptomics in APP/PS1dE9 mouse model and human AD tissue

   PMID:37429840 PMID:37589051

   Open questions at the time

   • In vivo renal-specific knockout phenotype not yet reported
   • Whether SLC22A17-mediated neurogenesis suppression is iron-dependent remains untested
6. 2024 High

   Showing that SLC22A17 promotes endothelial ferroptosis and represses tight junction gene transcription after cerebral ischemia established a direct pathological role for the receptor in blood-brain barrier disruption, validated by amelioration of BBB leakage upon knockdown in vivo.

   Evidence Reciprocal siRNA knockdown and lentiviral overexpression in human brain endothelial cells with permeability, electrical resistance, and ferroptosis marker assays; confirmed in mouse MCAO model

   PMID:38738428

   Open questions at the time

   • Mechanism by which SLC22A17 represses tight junction gene transcription not identified
   • Whether the effect is LCN2-dependent or iron-transport-dependent not dissected
7. 2025 High

   Discovery that brain-conditional Slc22a17 knockout causes postnatal lethality, iron overload, and neural stem cell apoptosis via dysregulated p62–Nrf2/HO-1 signaling provided the first genetic loss-of-function evidence that SLC22A17 is essential for brain iron homeostasis and neural development.

   Evidence Conditional knockout mouse with TurboID proximity labeling, immunoprecipitation identifying p62 interaction, and Nrf2/HO-1 pathway analysis with oxidative stress and cognitive behavioral readouts

   PMID:41397957

   Open questions at the time

   • Whether p62 interaction is direct or mediated through additional partners not resolved
   • Mechanism of iron efflux impairment downstream of Nrf2/HO-1 activation unclear
   • Contribution of LCN2-dependent versus LCN2-independent iron transport not separated
8. 2025 High

   Functional and structural studies demonstrated that SLC22A17 operates as a high-capacity, low-affinity iron transporter independent of LCN2, with a cryo-EM structure revealing a unique transmembrane loop (TML6) gating mechanism that diverges from other SLC22 transporters.

   Evidence (preprint) Cryo-EM structure of mouse BOCT1, functional iron transport assays, mutagenesis, and molecular dynamics simulations

   PMID:bio_10.1101_2025.06.28.662014

   Open questions at the time

   • Preprint not yet peer-reviewed
   • Human SLC22A17 structure not yet determined
   • Specific iron coordination residues in the transport pathway not fully validated by mutagenesis
9. 2025 Medium

   SLC22A17 was shown to promote ferroptosis in fibroblasts via iron-dependent mechanisms and to support TNBC cell proliferation through Akt/mTOR and JAK/STAT3 signaling, extending its pro-ferroptotic and pro-survival roles to non-neural tissues.

   Evidence siRNA knockdown and overexpression with ferroptosis marker quantification in urethral fibroblasts; siRNA silencing with flow cytometry and pathway immunoblotting in TNBC cell lines

   PMID:41212350 PMID:41386104

   Open questions at the time

   • Whether SLC22A17's oncogenic role in TNBC is iron-transport-dependent not tested
   • In vivo tumor models lacking
   • Mechanism linking SLC22A17 to Akt/mTOR activation unresolved

• Key unresolved questions include the atomic-resolution mechanism of iron transport through TML6 gating in human SLC22A17, whether its receptor and transporter functions are separable in vivo, and how the p62 interaction mechanistically couples to Nrf2/HO-1 signaling and iron efflux regulation.
• Human structure not determined
• No conditional kidney-specific knockout phenotype reported
• LCN2-dependent versus LCN2-independent iron transport contributions not separated in any tissue in vivo